For instance, the use of patient-derived colon cancer organoids has led to a more profound comprehension of the therapeutic response of the bispecific antibody cibisatamab, which targets carcinoembryonic antigen (CEA) [135]. Here, CEACAM5 is linked to colonic neoplasm.